These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29125591)

  • 41. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis.
    Quach OL; Hsu S
    JAMA Dermatol; 2016 Apr; 152(4):486-7. PubMed ID: 26720159
    [No Abstract]   [Full Text] [Related]  

  • 43. Infliximab and nephrotic syndrome.
    Chin G; Luxton G; Harvey JM
    Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 45. Persistent pruritus in psoriatic patients during administration of biologics.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Ishida-Yamamoto A
    J Dermatol; 2018 Aug; 45(8):e223. PubMed ID: 29512183
    [No Abstract]   [Full Text] [Related]  

  • 46. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
    Sockolov ME; Alikhan A; Zargari O
    J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum sickness due to infliximab in a patient with psoriasis.
    Krishnan RS; Hsu S
    J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
    Peccerillo F; Odorici G; Pellacani G; Conti A
    Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 50. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapeutics: Silencing psoriasis.
    Crow JM
    Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
    [No Abstract]   [Full Text] [Related]  

  • 53. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A promising step forward in psoriasis therapy.
    Stern RS
    JAMA; 2003 Dec; 290(23):3133-5. PubMed ID: 14679277
    [No Abstract]   [Full Text] [Related]  

  • 55. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
    van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
    Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
    [No Abstract]   [Full Text] [Related]  

  • 56. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppressive therapy in dermatology and PML.
    Sterry W; Bagot M; Ferrandiz C; Kragballe K; Papp K; Stingl G
    J Dtsch Dermatol Ges; 2009 Jan; 7(1):5. PubMed ID: 19138293
    [No Abstract]   [Full Text] [Related]  

  • 58. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
    Wahie S; Alexandroff A; Reynolds NJ
    Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
    [No Abstract]   [Full Text] [Related]  

  • 59. Ustekinumab: when everything else fails?
    Vitiello M; Grant A; Kerdel FA
    Int J Dermatol; 2011 Apr; 50(4):478-82. PubMed ID: 21413963
    [No Abstract]   [Full Text] [Related]  

  • 60. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
    Torres T; Raposo I; Selores M
    Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.